Search Results - "Scherber, Robyn"

How we diagnose and treat systemic mastocytosis in adults by Scherber, Robyn M., Borate, Uma

“…Summary Rapid advances in the understanding of the molecular biology, data from translational and clinical trials, and retrospective analyses has influenced…”
Get full text

The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies by Craver, Brianna M, El Alaoui, Kenza, Scherber, Robyn M, Fleischman, Angela G

“…Hematopoietic stem cells (HSCs) maintain an organism's immune system for a lifetime, and derangements in HSC proliferation and differentiation result in…”
Get full text

Management of challenging myelofibrosis after JAK inhibitor failure and/or progression by Scherber, Robyn M., Mesa, Ruben A.

“…The myeloproliferative neoplasms (MPNs) encompass a heterogenous set of diseases that have variable survival, but in the setting of treatment refractory and…”
Get full text

Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States by Verstovsek, Srdan, Yu, Jingbo, Scherber, Robyn M., Verma, Sumit, Dieyi, Christopher, Chen, Chien-Cheng, Parasuraman, Shreekant

“…This analysis examined trends in incidence and survival among US adults with myeloproliferative neoplasms, including essential thrombocythemia (ET; n =…”
Get full text

Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia by Pemmaraju, Naveen, Gerds, Aaron T., Yu, Jingbo, Parasuraman, Shreekant, Shah, Anne, Xi, Ann, Kumar, Shambhavi, Scherber, Robyn M., Verstovsek, Srdan

“…Patients with polycythemia vera (PV) and essential thrombocythemia (ET) have increased thrombotic risk. This retrospective, real-world analysis of Medicare…”
Get full text

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development by Mesa, Ruben A., Scherber, Robyn M., Dueck, Amylou C., Geyer, Holly L.

“…Myeloproliferative neoplasms (essential thrombocythemia, ET; polycythemia vera, PV; myelofibrosis, MF) are monoclonal malignancies associated with genomic…”
Get full text

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide by Harrison, Claire N., Mead, Adam J., Panchal, Anesh, Fox, Sonia, Yap, Christina, Gbandi, Emmanouela, Houlton, Aimee, Alimam, Samah, Ewing, Joanne, Wood, Marion, Chen, Frederick, Coppell, Jason, Panoskaltsis, Nicki, Knapper, Steven, Ali, Sahra, Hamblin, Angela, Scherber, Robyn, Dueck, Amylou C., Cross, Nicholas C.P., Mesa, Ruben, McMullin, Mary Frances

“…Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage,…”
Get full text

Real-world patient characteristics and treatment patterns of ruxolitinib among patients with advanced essential thrombocythemia at community clinical practice by Verstovsek, Srdan, Amoloja, Theresa, Scherber, Robyn M., Yu, Jingbo

“…•Ruxolitinib (JAK inhibitor) is approved in myelofibrosis and polycythemia vera.•Spontaneous ruxolitinib use for essential thrombocythemia (ET) has been…”
Get full text

Trends in overall mortality among US veterans with primary myelofibrosis by Tashi, Tsewang, Yu, Jingbo, Pandya, Shivani, Dieyi, Christopher, Scherber, Robyn, Parasuraman, Shreekant

“…Primary myelofibrosis [PMF] is a myeloproliferative neoplasm associated with reduced overall survival (OS). Management strategies for PMF have evolved over the…”
Get full text

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis by Ronner, Lukas, Podoltsev, Nikolai, Gotlib, Jason, Heaney, Mark L., Kuykendall, Andrew T., O'Connell, Casey, Shammo, Jamile, Fleischman, Angela G., Scherber, Robyn M., Mesa, Ruben, Yacoub, Abdulraheem, Perkins, Cecelia, Meckstroth, Shelby, Behlman, Lindsey, Chiaramonte, Matthew, Salehi, Mahta, Ziadkhanpour, Kimia, Nguyen, Hellen, Siwoski, Olivia, Hung, Annie Kwok, Janania Martinez, Michelle, Nguyen, Jenny, Patel, Sagar, Kollipara, Revathi, Dave, Ami, Randall, Megan, Grant, Michael, Harrison, Mitchell, Fernandez Soto, Paola, Tremblay, Douglas, Hoffman, Ronald, Moshier, Erin, Mascarenhas, John

“…There are unresolved questions regarding the association between persistent leukocytosis and risk of thrombosis and disease evolution in polycythemia vera…”
Get full text

Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF by Scherber, Robyn M, Mesa, Ruben A

“…Myelofibrosis (MF) is the most aggressive form of Philadelphia chromosome-negative myeloproliferative neoplasm, and it is complicated by severe symptom burden,…”
Get full text

Assessing Symptom Burden in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Patients by Garza, Juan, Anderson, Jane Margret, Scherber, Robyn M.

“…Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes are rare types of chronic myeloid hematologic neoplasms. Patients with overlap syndrome…”
Get full text

Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions by Surapaneni, Prathibha, Scherber, Robyn M.

“…Purpose of Review Myeloproliferative neoplasms (MPNs) have a high symptom burden that affects functional status, emotional well-being, and quality of life for…”
Get full text

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients by Scherber, Robyn, Dueck, Amylou C., Johansson, Peter, Barbui, Tiziano, Barosi, Giovanni, Vannucchi, Alessandro M., Passamonti, Francesco, Andreasson, Bjorn, Ferarri, Maria L., Rambaldi, Alessandro, Samuelsson, Jan, Birgegard, Gunnar, Tefferi, Ayalew, Harrison, Claire N., Radia, Deepti, Mesa, Ruben A.

“…Symptomatic burden in myeloproliferative neoplasms is present in most patients and compromises quality of life. We sought to validate a broadly applicable…”
Get full text

Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)‐I study by Kosiorek, Heidi E., Scherber, Robyn M., Geyer, Holly L., Verstovsek, Srdan, Langlais, Blake T., Mazza, Gina L., Gotlib, Jason, Gupta, Vikas, Padrnos, Leslie J., Palmer, Jeanne M., Fleischman, Angela, Mesa, Ruben A., Dueck, Amylou C.

Get full text

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms by Scherber, Robyn M., Kosiorek, Heidi E., Senyak, Zhenya, Dueck, Amylou C., Clark, Matthew M., Boxer, Michael A., Geyer, Holly L., McCallister, Archie, Cotter, Mary, Van Husen, Barbara, Harrison, Claire N., Mesa, Ruben A.

“…BACKGROUND Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only…”
Get full text

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients by Geyer, Holly L., Scherber, Robyn M., Dueck, Amylou C., Kiladjian, Jean-Jacques, Xiao, Zhijian, Slot, Stefanie, Zweegman, Sonja, Sackmann, Federico, Fuentes, Ana Kerguelen, Hernández-Maraver, Dolores, Döhner, Konstanze, Harrison, Claire N., Radia, Deepti, Muxi, Pablo, Besses, Carlos, Cervantes, Francisco, Johansson, Peter L., Andreasson, Bjorn, Rambaldi, Alessandro, Barbui, Tiziano, Vannucchi, Alessandro M., Passamonti, Francesco, Samuelsson, Jan, Birgegard, Gunnar, Mesa, Ruben A.

“…Symptom burden in myeloproliferative neoplasms (MPNs) is heterogeneous even among patients within the same MPN diagnosis. Using cluster analysis from…”
Get full text

Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care by Christensen, Sarah F, Scherber, Robyn M, Mazza, Gina L, Dueck, Amylou C, Brochmann, Nana, Andersen, Christen L, Hasselbalch, Hans C, Mesa, Ruben A, Geyer, Holly L

“…Abstract Background Patients with Philadelphia-negative Myeloproliferative Neoplasms (MPN) suffer from numerous symptoms and decreased quality of life. Smoking…”
Get full text

Elevated Hemoglobin or Hematocrit Level by Scherber, Robyn M, Mesa, Ruben A

Get full text

Evaluating Elevated Hemoglobin—Reply by Scherber, Robyn M, Mesa, Ruben A

Get full text